



**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Roctavian™ (valoctocogene roxaparvovec-rvox)

DATE OF MEDICATION REQUEST: / /

SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER: Male Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY

1. Does the patient have severe congenital factor VIII deficiency, confirmed by factor VIII activity <1 IU/dL testing? Yes No
2. Have other bleeding disorders been ruled out? Yes No
3. Is the patient AAV serotype 5 (AAV5) antibody negative as determined by an FDA-approved or CLIA-compliant test? Yes No
4. Does the patient have an active infection (acute or uncontrolled chronic)? Yes No
5. Does the patient have significant hepatic fibrosis (stage 3 or 4) or cirrhosis? Yes No
6. Is the patient on a stable dose of exogenous factor VIII for prevention of bleeding episodes? Yes No

a. Regimen and start date: _____

(Form continued on next page.)

Fax to DHHS; medication is administered in inpatient setting:

Phone: 1-603-271-9384

Fax: 1-603-314-8101

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Review Date: 01/29/2024





**New Hampshire Medicaid Fee-for-Service Program
Prior Authorization Drug Approval Form**

Roctavian™ (valoctocogene roxaparvovec-rvox)

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SECTION III: CLINICAL HISTORY

- 7. Does the patient have a hypersensitivity to mannitol? Yes No
- 8. Has the patient received prior hemophilia adeno-associated virus vector-based gene therapy? Yes No
- 9. Is the patient negative for factor VIII inhibitor titers on initial test or re-test? Yes No
- 10. Is the patient received a bypass agent (e.g. Feiba)? Yes No
- 11. Will the liver function be assessed after Roctavian™ dose according to a facility protocol? Yes No
 - a. Attach copy of baseline liver function tests.
- 12. Does the patient have any of the following: Yes No
 - Hepatitis B
 - Hepatitis C
 - Non-alcoholic fatty liver disease
 - Chronic alcohol consumption
 - Non-alcoholic steatohepatitis
 - Advanced age
- 13. If yes to question 12, will the patient have regular liver ultrasounds and testing for alpha-fetoprotein elevation? Yes No
- 14. Attach protocol for post-Roctavian™ monitoring.

Please provide any additional information that would help in the decision-making process. If additional space is needed, please use a separate sheet.

I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

PRESCRIBER'S SIGNATURE: _____ **DATE:** _____

Facility where infusion to be provided: _____

Medicaid Provider Number of Facility: _____

Fax to DHHS; medication is administered in inpatient setting:
Phone: 1-603-271-9384
Fax: 1-603-314-8101

